Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

PubMed  Google Scholar 

Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061.

PubMed  Google Scholar 

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–96.

PubMed  PubMed Central  Google Scholar 

Lee JY, Kim S, Kim YT, Lim MC, Lee B, Jung KW et al. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18:601.

Bartoletti M, Musacchio L, Giannone G, Tuninetti V, Bergamini A, Scambia G, et al. Emerging molecular alterations leading to histology-specific targeted therapies in ovarian cancer beyond PARP inhibitors. Cancer Treat Rev. 2021;101:102298.

CAS  PubMed  Google Scholar 

Matthews HK, Bertoli C, de Bruin R. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74–88.

CAS  PubMed  Google Scholar 

Fischer M, Müller GA. Cell cycle transcription control: DREAM/MuvB and RB-E2F complexes. Crit Rev Biochem Mol Biol. 2017;52:638–62.

CAS  PubMed  Google Scholar 

Müller GA, Wintsche A, Stangner K, Prohaska SJ, Stadler PF, Engeland K. The CHR site: definition and genome-wide identification of a cell cycle transcriptional element. Nucleic Acids Res. 2014;42:10331–50.

PubMed  PubMed Central  Google Scholar 

Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 2016;44:164–74.

CAS  PubMed  Google Scholar 

Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 2016;44:6070–86.

CAS  PubMed  PubMed Central  Google Scholar 

Jin Y, Qi G, Chen G, Wang C, Fan X. Association between B-Myb proto-oncogene and the development of malignant tumors. Oncol Lett. 2021;21:166.

CAS  PubMed  PubMed Central  Google Scholar 

Cicirò Y, Sala A. MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. Oncogenesis. 2021;10:19.

PubMed  PubMed Central  Google Scholar 

Musa J, Aynaud MM, Mirabeau O, Delattre O, Grünewald TG. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 2017;8:e2895.

CAS  PubMed  PubMed Central  Google Scholar 

Luo Y, Ye GY, Qin SL, Yu MH, Mu YF, Zhong M. ATAD2 overexpression identifies colorectal cancer patients with poor prognosis and drives proliferation of cancer cells. Gastroenterol Res Pract. 2015;2015:936564.

PubMed  PubMed Central  Google Scholar 

Wang JH, Yu TT, Li Y, Hao YP, Han L, Xu KY, et al. Silence of ATAD2 inhibits proliferation of colorectal carcinoma via the Rb-E2F1 signaling. Eur Rev Med Pharmacol Sci. 2020;24:6055–63.

PubMed  Google Scholar 

Zheng L, Li T, Zhang Y, Guo Y, Yao J, Dou L, et al. Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer. Oncol Rep. 2015;33:2337–44.

CAS  PubMed  Google Scholar 

Caron C, Lestrat C, Marsal S, Escoffier E, Curtet S, Virolle V, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29:5171–81.

CAS  PubMed  Google Scholar 

Ciró M, Prosperini E, Quarto M, Grazini U, Walfridsson J, McBlane F, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69:8491–8.

PubMed  Google Scholar 

Huang J, Yang J, Lei Y, Gao H, Wei T, Luo L, et al. An ANCCA/PRO2000-miR-520a-E2F2 regulatory loop as a driving force for the development of hepatocellular carcinoma. Oncogenesis. 2016;5:e229.

CAS  PubMed  PubMed Central  Google Scholar 

Liu Q, Liu H, Li L, Dong X, Ru X, Fan X, et al. ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation. Int J Oncol. 2020;56:219–31.

CAS  PubMed  Google Scholar 

Nayak A, Dutta M, Roychowdhury A. Emerging oncogene ATAD2: signaling cascades and therapeutic initiatives. Life Sci. 2021;276:119322.

CAS  PubMed  Google Scholar 

Baggiolini A, Callahan SJ, Montal E, Weiss JM, Trieu T, Tagore MM, et al. Developmental chromatin programs determine oncogenic competence in melanoma. Science. 2021;373:eabc1048.

CAS  PubMed  PubMed Central  Google Scholar 

Liu J, Li C, Wang J, Xu D, Wang H, Wang T, et al. Chromatin modifier MTA1 regulates mitotic transition and tumorigenesis by orchestrating mitotic mRNA processing. Nat Commun. 2020;11:4455.

CAS  PubMed  PubMed Central  Google Scholar 

Zhou X, Ji H, Ye D, Li H, Liu F, Li H, et al. Knockdown of ATAD2 inhibits proliferation and tumorigenicity through the Rb-E2F1 pathway and serves as a novel prognostic indicator in gastric cancer. Cancer Manag Res. 2020;12:337–51.

CAS  PubMed  PubMed Central  Google Scholar 

Krakstad C, Tangen IL, Hoivik EA, Halle MK, Berg A, Werner HM, et al. ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma. Oncotarget. 2015;6:28440–52.

PubMed  PubMed Central  Google Scholar 

Kalashnikova EV, Revenko AS, Gemo AT, Andrews NP, Tepper CG, Zou JX, et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res. 2010;70:9402–12.

CAS  PubMed  PubMed Central  Google Scholar 

Nelson L, Tighe A, Golder A, Littler S, Bakker B, Moralli D, et al. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity. Nat Commun. 2020;11:822.

CAS  PubMed  PubMed Central  Google Scholar 

Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198–208.

CAS  PubMed  Google Scholar 

Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.

Google Scholar 

Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics. 2009;2:34.

PubMed  PubMed Central  Google Scholar 

Konstantinopoulos PA, Fountzilas E, Pillay K, Zerbini LF, Libermann TA, Cannistra SA, et al. Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer. BMC Med Genomics. 2008;1:59.

PubMed  PubMed Central  Google Scholar 

Liu Q, Sui R, Li R, Miao J, Liu J. Biological characteristics of Taxol‑resistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53. Mol Med Rep. 2015;11:1292–7.

CAS  PubMed  Google Scholar 

Murakami H, Ito S, Tanaka H, Kondo E, Kodera Y, Nakanishi H. Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis. Anticancer Res. 2013;33:4299–307.

CAS  PubMed  Google Scholar 

Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, et al. A biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res. 2020;26:4767–76.

CAS  PubMed  Google Scholar 

Fernández-Montalván AE, Berger M, Kuropka B, Koo SJ, Badock V, Weiske J, et al. Isoform-selective ATAD2 chemical probe with novel chemical structure and unusual mode of action. ACS Chem Biol. 2017;12:2730–6.

PubMed  PubMed Central  Google Scholar 

Yao D, Zhang J, Wang J, Pan D, He Z. Discovery of novel ATAD2 bromodomain inhibitors that trigger apoptosis and autophagy in breast cells by structure-based virtual screening. J Enzym Inhib Med Chem. 2020;35:713–25.

CAS  Google Scholar 

Wang AQ, Lv M, Xu YH, Xie PM, Dong YY. MiR-200b-5p inhibits proliferation of ovarian cancer cells by targeting ATAD2 and regulating PI3K/AKT signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24:9860–8.

PubMed  Google Scholar 

Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240–53.

PubMed  Google Scholar 

Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25:114–32.

CAS  PubMed  Google Scholar 

Uxa S, Bernhart SH, Mages C, Fischer M, Kohler R, Hoffmann S, et al. DREAM and RB cooperate to induce gene repression and cell-cycle arrest in response to p53 activation. Nucleic Acids Res. 2019;47:9087–103.

CAS  PubMed  PubMed Central  Google Scholar 

Iness AN, Felthousen J, Ananthapadmanabhan V, Sesay F, Saini S, Guiley KZ, et al. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb. Oncogene. 2019;38:1080–92.

CAS  PubMed  Google Scholar 

Uxa S, Castillo-Binder P, Kohler R, Stangner K, Müller GA, Engeland K. Ki-67 gene expression. Cell Death Differ. 2021;28:3357–70.

CAS  PubMed  PubMed Central  Google Scholar 

Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y et al. B-Myb is up-regulated and promotes cell growth and motility in non-small cell lung cancer. Int J Mol Sci. 2017;18:860.

Santilli G, Schwab R, Watson R, Ebert C, Aronow BJ, Sala A. Temperature-dependent modification and activation of B-MYB: implications for cell survival. J Biol Chem. 2005;280:15628–34.

CAS  PubMed  Google Scholar 

Tarasov KV, Tarasova YS, Tam WL, Riordon DR, Elliott ST, Kania G, et al. B-MYB is essential for normal cell cycle progression and chromosomal stability of embryonic stem cells. PLoS ONE.